Mission & Vision

Mission

A global biopharmaceutical company dedicated to developing innovative vaccines for the prevention of infectious diseases, grounded in strong research and development capabilities in life sciences. Our mission is to contribute to public health and improve quality of life by providing safer, more cost-effective, and highly efficient vaccine solutions that help prevent the spread of infectious diseases.

01
Life Science R&D
02
Development of Innovative Vaccines for Infectious Disease Prevention
03
Providing Safe, Cost-Effective, and Efficient Vaccine Solutions
04
Contributing to the Prevention of Disease Spread and the Advancement of Global Health

Vision

Our top priority is to protect lives from viruses and infectious diseases through innovative vaccine research and development.

01
Leading Next-Generation Vaccine Development – Researching Vaccines for Foot-and-Mouth Disease and Other Infectious Diseases
02
Strengthening Fundamental Research Capabilities – Establishing Rapid-Response Vaccine Platforms
03
Advancing as a Global Vaccine Company – Expanding International
04
Ensuring Safe and Sustainable Vaccine Supply – Providing Reliable and High-Quality Vaccines

"Safer. More Effective. For Everyone."
Pioneering a Healthier Future Through Innovative Vaccines.

Building a Business Platform Through
VLP-Based Next-Generation Vaccine and
Therapeutic Development

  • Building a Vaccine Platform Specialized in Animal Infectious Diseases

    Building a Proprietary Vaccine Platform by Leveraging Our Strength in Animal Disease Vaccines and Advancing R&D Efficiency

    Foot-and-Mouth Disease Virus (FMDV) Porcine Circovirus Type 2 (PCV2) African Swine Fever (ASF) Hepatitis E Virus (HEV) Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Dengue Virus (DENV)

  • Virus-like particle (VLP) vaccine technology platform

    A recombinant vaccine platform using virus-like particles (VLPs) with the same immunogenicity as real viruses

    Non-envelope VLP Envelope VLP Bacteriophage VLP Spycatcher-Spytag VLP

  • A Development System for Vaccine Immune Adjuvants

    An adjuvant platform that enhances vaccine efficacy through improved antibody induction, prolonged immunity, and reduced dosage and frequency

    Bacteriophage VLP-Based Adjuvant T-cell/B-cell Stimulating Epitope-Fused Adjuvant Cytokine Antiviral agents

  • Highly Skilled Vaccine Development Team and Collaborative R&D Partners

    Experienced researchers in domestic vaccine development for high-risk infectious diseases such as FMD, in collaboration with leading partners in advanced vaccine technologies

    Animal and Plant Quarantine Agency (APQA) Foot-and-Mouth Disease Vaccine Research Center CAVAC Co., Ltd XP Bio Korea Institute of Science and Technology (KIST) BionLifescience

A Specialized Vaccine Manufacturer Utilizing Innovative Recombinant Technology